Ann: Race releases complete cardio-protection data & video, page-63

I've been waiting for Seagen to release their revenue projections to the SEC. Financial analysis and background to transactions are usually published to the SEC when buyouts occur.

In this case Pfizer are buying Seagen for US $43B.

https://www.pfizer.com/news/press-r...etail/pfizer-invests-43-billion-battle-cancer

Whilst at a commercial stage and generating significant revenue, Seagen transaction does give us some insights into potential revenue and scale of indications needed to achieve a blockbuster-level buyout transaction. I do think scale of Cardioprotect and FTO opportunities allow RACE to be put into category of blockbuster future sales and potential for a blockbuster buyout (the market just needs to recognise the potential and unique risk profile of RAC due to the impressive history). The market then in response to RAC news flow needs to move the SP closer to intrinsic values discussed at length here an elsewhere.

The Seagen revenue projections can be found here (page 55):

https://www.sec.gov/Archives/edgar/data/1060736/000119312523102294/d484035dprem14a.htm#toc484035_90



IMO and not advice ... scale of Zantrene revenue potential is similar to Seagen's pipeline ...